Item 5. Market for Registrant’s Common Equity
Item 5. Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities
Our common stock is listed and traded under the ticker symbol “PCRX” on the Nasdaq Global Select Market. As of February 25, 2026, we had nine holders of record of our common stock. The number of record holders is based on the actual number of holders registered on the books of our transfer agent and does not reflect the substantially greater amount of holders of shares in “street name,” whose shares are held of record by banks, brokers and other financial institutions.
Performance Graph
The following graph and table shows the value of an investment of $100.00 made on December 31, 2020—the last trading day of 2020—in each of Pacira BioSciences, Inc. (PCRX), the Nasdaq Composite Index (^IXIC), the Nasdaq Biotechnology Index (^NBI) and the S&P Pharmaceuticals Select Index (^SPSIPH). The three indices included are for comparative purposes only and do not necessarily reflect management’s opinion that such indices are an appropriate measure of the relative performance of our common stock. All results assume the reinvestment of dividends, if any, and are calculated as of December 31 st of each year. The historical stock price performance of our common stock and the indices shown in this performance graph is not necessarily indicative of future stock price performance.
Comparison of Five-Year Cumulative Total Returns Among
Pacira BioSciences, Inc., the Nasdaq Composite Index,
the Nasdaq Biotechnology Index and the S&P Pharmaceuticals Select Index
Cumulative Total Return as of December 31,
2020 2021 2022 2023 2024 2025
Pacira BioSciences, Inc. (PCRX) $ 100.00 $ 100.55 $ 64.52 $ 56.38 $ 31.48 $ 43.25
Nasdaq Composite Index (^IXIC) $ 100.00 $ 121.39 $ 81.21 $ 116.47 $ 149.83 $ 180.33
Nasdaq Biotechnology Index (^NBI) $ 100.00 $ 99.37 $ 88.53 $ 91.84 $ 90.58 $ 119.92
S&P Pharmaceuticals Select Index (^SPSIPH) $ 100.00 $ 88.76 $ 78.82 $ 79.90 $ 82.47 $ 107.22
Dividend Policy
We have never declared or paid any dividends on our common stock. We currently intend to retain any future earnings to finance the future development and expansion of our business, and as such we do not expect to pay any dividends on our
Pacira BioSciences, Inc. | 2025 Annual Report on Form 10-K | 77
Table of Contents
common stock in the foreseeable future. The payment of any future dividends would be at the discretion of our board of directors and will depend on our financial condition, results of operations, capital requirements, restrictions contained in the agreements governing our indebtedness, provisions of applicable law and any other factors our board of directors deems relevant.
Purchases of Equity Securities by the Registrant
The following table provides information on our share repurchases during the quarter ended December 31, 2025:
Issuer Purchases of Equity Securities
Period Total Number
of Shares Purchased Average Price
Paid Per Share (1)
Total Number of Shares Purchased as Part of Publicly Announced Plans or Programs (2)
Approximate Dollar Value of Shares that May Yet be Purchased Under the Plans or Programs (1)
October 1, 2025 – October 31, 2025 — $ — — $ 199,998,530
November 1, 2025 – November 30, 2025 768,164 $ 23.41 768,164 $ 182,014,229
December 1, 2025 –December 31, 2025 1,236,528 $ 25.89 1,236,528 $ 150,001,371
Total 2,004,692 $ 24.94 2,004,692 $ 150,001,371
(1) The average price paid per share excludes less than $0.1 million of broker fees and $1.0 million of excise tax incurred on share repurchases for the three months ended December 31, 2025. The remaining authorization outstanding for repurchases of common stock also excludes broker fees and the excise tax incurred.
(2) Our Board of Directors has authorized the repurchase of common stock under a share repurchase program adopted and announced in April 2025. The share repurchase program authorizes the Company to purchase up to an aggregate of $300.0 million of the Company’s outstanding common stock. Repurchases under this program may be made at management’s discretion on the open market or through privately negotiated transactions, including plans that comply with Rule 10b5-1 under the Exchange Act. The share repurchase program may be suspended or discontinued at any time by the Company and has an expiration date of December 31, 2026.
The timing of any repurchases and the actual number of shares repurchased will depend on a variety of factors, including our stock price, corporate and regulatory requirements, tax implications, restrictions under our debt obligations, other uses for capital, impacts on the value of remaining shares, and market and economic conditions.
Refer to Note 13, Stockholders’ Equity , to our consolidated financial statements included herein for more information on our share repurchases.
Item 6. [Reserved]